✦ LIBER ✦

The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers

✍ Scribed by Harri Kanerva; Olavi Kilkku; Esa Heinonen; Antti Helminen; Juha Rouru; Simo Tarpila; Mika Scheinin; Risto Huupponen; Imre Klebovich; Sandor Drabant; Arto Urtti

Publisher: John Wiley and Sons
Year: 1999
Tongue: English
Weight: 201 KB
Volume: 20
Category: Article
ISSN: 0142-2782
DOI: 10.1002/(sici)1099-081x(199910)20:7<327::aid-bdd192>3.0.co;2-8

No coin nor oath required. For personal study only.

✦ Synopsis

The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2 to 50 mg in 18 healthy male volunteers. In the second study doses from 50 to 150 mg were investigated in 14 healthy males in a double-blind, placebo-controlled, dose escalation study. Deramciclane was rapidly absorbed from the GI-tract and T max was 2 -4 h. The elimination half-life increased from about 20 h to about 32 h with the increasing dose. Nevertheless, the AUC 0-values increased linearly within the studies over the dose ranges of 3 -50 and 50 -150 mg. However, the increase was more than the ratio of the dose over the total dose range of 3 -150 mg. Therefore, non-linear pharmacokinetics of deramciclane at high doses cannot be excluded. N-desmethyl deramciclane, which is the active metabolite of deramciclane, was determined in plasma. C max was reached at about 6 h. The AUC 0-48 h for the N-desmethyl metabolite was about one third of the AUC 0-of the parent compound and the ratio remained constant at each dose level. Deramciclane was safe, and was well tolerated at each dose level.

📜 SIMILAR VOLUMES

Single dose pharmacokinetics and bioavai

Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers

✍ Michael J. Lamson; John P. Sabo; Thomas R. Macgregor; Joseph W. Pav; Lois Rowlan 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

The results of two randomized, single-dose, crossover bioavailability studies are presented which describe the pharmacokinetics and oral bioavailability of nevirapine, a novel nonnucleoside antiretroviral drug. In the first study 12 healthy male volunteers received nevirapine 15 mg via short-term i.

Single dose pharmacokinetics of HEPP, a

Single dose pharmacokinetics of HEPP, a new anticonvulsant in normal healthy volunteers

✍ Dinora F. González-Esquivel; Francisco Rubio-Donnadieu; Guillermo Carvajal S.; H 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

The pharmacokinetics and the dose proportionality of a new anticonvulsant compound, HEPP (D,L-3-hydroxy-3-ethyl-3-phenylpropionamide) was studied in healthy male volunteers as part of the pharmacological evaluation for new drugs. Study was performed administering doses of 250, 375, 500 and 625 mg of

Dose proportionality and comparison of s

Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16 455) and its enantiomers in healthy male volunteers

✍ Doris K. Robbins; Mark A. Castles; David J. Pack; Vijay O. Bhargava; Scott J. We 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB 👁 1 views

The pharmacokinetics and dose proportionality of fexofenadine, a new non-sedating antihistamine, and its enantiomers were characterized after single and multiple-dose administration of its hydrochloride salt. A total of 24 healthy male volunteers (31 98 years) received oral doses of 20, 60, 120 and

PHARMACOKINETICS AND SAFETY OF SINGLE IN

PHARMACOKINETICS AND SAFETY OF SINGLE INTRAVENOUS AND ORAL DOSES OF DOLASETRON MESYLATE IN HEALTHY WOMEN

✍ ANTHER C. F. KEUNG; HÉLÈNE LANDRIAULT; MARC LEFEBVRE; DENIS GOSSARD; ELLEN E. DE 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 2 views

Twenty-four healthy women received 2´4 mg kg 71 dolasetron mesylate (1´8 mg kg 71 dolasetron base) by a 10 min intravenous administration and by oral administration. Pharmacokinetics of dolasetron and of its active reduced metabolite MDL 74 156 were monitored for 48 h in plasma. Urine was collected

Dose proportionality of reboxetine enant

Dose proportionality of reboxetine enantiomers in healthy male volunteers

✍ E. Rey; P. Dostert; Ph. d'Athis; M.G. Jannuzzo; I. Poggesi; G. Olive 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

Reboxetine is a racemic mixture of FCE 22071 and FCE 21684 enantiomers. The pharmacokinetics of the enantiomers of reboxetine were observed to be linear in male healthy subjects (n = 6) after the administration of 1.5, 3, 4.5 mg dose of reboxetine as solutions. Kinetic analysis was based on chiral H

Pharmacokinetics of deramciclane in dogs

Pharmacokinetics of deramciclane in dogs after single oral and intravenous dosing and multiple oral dosing

✍ Harri Kanerva; Hannele Huuskonen; Anneli Alhonen-Raatesalmi; Timo Nevalainen; Ar 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB 👁 1 views

The pharmacokinetics of a new serotonin 5-HT 2 antagonist, deramciclane, was studied. Single oral doses of 1, 3, 6 and 10 mg kg -1 and intravenous doses of 1, 3 and 6 mg kg -1 were administered in beagle dogs. Moreover, the steady state pharmacokinetics of 1, 3 and 6 mg kg -1 doses were studied. Der